Search
Tyramine
go.drugbank.com/drugs/DB08841InvestigationalNutraceuticalThere have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.
NCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
Arbekacin
go.drugbank.com/drugs/DB06696InvestigationalAn semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).
OSI-461
go.drugbank.com/drugs/DB05415InvestigationalOSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Depatuxizumab mafodotin
go.drugbank.com/drugs/DB11731InvestigationalDepatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Ceftaroline fosamil
go.drugbank.com/drugs/DB06590ApprovedInvestigationalCeftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneu...
Synonyms: (6R,7R)-7-[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylateIbopamine
go.drugbank.com/drugs/DB13316ExperimentalCategories: Compounds used in a research, industrial, or household settingBB 21217
go.drugbank.com/drugs/DB17373InvestigationalBB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP
Viralym-C
go.drugbank.com/drugs/DB17975InvestigationalIt was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.